MRD’s Potential Role in Treating Acute Myeloid Leukemia
0 Visningar
• 07/04/23
0
0
Bädda in
administrator
Prenumeranter
Harry Erba, MD, PhD; Alexander E. Perl, MD; Eunice Wang, MD; and Jorge E. Cortes, MD, debate the current value of minimal residual disease testing for therapeutic decision-making in acute myeloid leukemia and identify the needs to be addressed before use in standard practice.
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna